Recombinant snake venom metalloproteinase inhibitor BJ46A inhibits invasion and metastasis of B16F10 and MHCC97H cells through reductions of matrix metalloproteinases 2 and 9 activities

2013 ◽  
Vol 24 (5) ◽  
pp. 461-472 ◽  
Author(s):  
Ming-Kai Ji ◽  
Yi Shi ◽  
Jian-Wen Xu ◽  
Xu Lin ◽  
Jian-Yin Lin
Keyword(s):  
Matrix Metalloproteinases ◽  
Snake Venom ◽  
Invasion And Metastasis ◽  
Metalloproteinase Inhibitor ◽  
Snake Venom Metalloproteinase

PO41, a snake venom metalloproteinase inhibitor isolated from Philander opossum serum

Toxicon ◽  
2003 ◽  
Vol 42 (6) ◽  
pp. 621-628 ◽  
Author(s):  
Patrı́cia B Jurgilas ◽  
Ana G.C Neves-Ferreira ◽  
Gilberto B Domont ◽  
Jonas Perales
Keyword(s):  
Snake Venom ◽  
Metalloproteinase Inhibitor ◽  
Snake Venom Metalloproteinase

BJ46a, a snake venom metalloproteinase inhibitor

2001 ◽  
Vol 268 (10) ◽  
pp. 3042-3052 ◽  
Author(s):  
Richard H. Valente ◽  
Bojan Dragulev ◽  
Jonas Perales ◽  
Jay W. Fox ◽  
Gilberto B. Domont
Keyword(s):  
Snake Venom ◽  
Metalloproteinase Inhibitor ◽  
Snake Venom Metalloproteinase

scholarly journals Structural and Functional Analyses of DM43, a Snake Venom Metalloproteinase Inhibitor fromDidelphis marsupialisSerum

2002 ◽  
Vol 277 (15) ◽  
pp. 13129-13137 ◽  
Author(s):  
Ana G. C. Neves-Ferreira ◽  
Jonas Perales ◽  
Jay W. Fox ◽  
John D. Shannon ◽  
Débora L. Makino ◽  
...  
Keyword(s):  
Snake Venom ◽  
Metalloproteinase Inhibitor ◽  
Snake Venom Metalloproteinase ◽  
Functional Analyses

scholarly journals The Search for Natural and Synthetic Inhibitors That Would Complement Antivenoms as Therapeutics for Snakebite Envenoming

Toxins ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 451
Author(s):  
José María Gutiérrez ◽  
Laura-Oana Albulescu ◽  
Rachel H. Clare ◽  
Nicholas R. Casewell ◽  
Tarek Mohamed Abd Abd El-Aziz ◽  
...  
Keyword(s):  
Snake Venom ◽  
Serine Proteinase ◽  
Global Strategy ◽  
World Health ◽  
Wide Range ◽  
Variable Chemical ◽  
Snake Venom Metalloproteinase ◽  
Health Organization ◽  
The Impact ◽  
Natural And Synthetic

A global strategy, under the coordination of the World Health Organization, is being unfolded to reduce the impact of snakebite envenoming. One of the pillars of this strategy is to ensure safe and effective treatments. The mainstay in the therapy of snakebite envenoming is the administration of animal-derived antivenoms. In addition, new therapeutic options are being explored, including recombinant antibodies and natural and synthetic toxin inhibitors. In this review, snake venom toxins are classified in terms of their abundance and toxicity, and priority actions are being proposed in the search for snake venom metalloproteinase (SVMP), phospholipase A2 (PLA2), three-finger toxin (3FTx), and serine proteinase (SVSP) inhibitors. Natural inhibitors include compounds isolated from plants, animal sera, and mast cells, whereas synthetic inhibitors comprise a wide range of molecules of a variable chemical nature. Some of the most promising inhibitors, especially SVMP and PLA2 inhibitors, have been developed for other diseases and are being repurposed for snakebite envenoming. In addition, the search for drugs aimed at controlling endogenous processes generated in the course of envenoming is being pursued. The present review summarizes some of the most promising developments in this field and discusses issues that need to be considered for the effective translation of this knowledge to improve therapies for tackling snakebite envenoming.

A fibrinolytic snake venom metalloproteinase, mutalysin-II, with antiplatelet activity and targeting capability toward glycoprotein GPIbα and glycoprotein GPVI

Biochimie ◽  
2021 ◽  
Vol 184 ◽  
pp. 1-7
Author(s):  
Eladio.F. Sanchez ◽  
Valeria.G. Alvarenga ◽  
Luciana.S. Oliveira ◽  
Débora.L. Oliveira ◽  
Maria.I. Estevao- Costa ◽  
...  
Keyword(s):  
Snake Venom ◽  
Antiplatelet Activity ◽  
Snake Venom Metalloproteinase
Sign in / Sign up

Export Citation Format

Share Document